EC-18 for Management of Chemotherapy-Induced Neutropenia in Patients With Advanced BC Receiving Low Febrile Neutropenia Risk Chemotherapy: Dose-Escalation, Open-label, Trial to Assess Safety and Tolerability of EC-18
Phase of Trial: Phase II
Latest Information Update: 03 Aug 2018
At a glance
- Drugs Mosedipimod (Primary)
- Indications Febrile neutropenia
- Focus Proof of concept; Therapeutic Use
- Sponsors Enzychem Lifesciences Corporation
- 19 Oct 2017 Planned End Date changed from 1 Mar 2019 to 31 Mar 2019.
- 19 Oct 2017 Planned primary completion date changed from 1 Sep 2018 to 31 Dec 2018.
- 08 Aug 2017 Planned initiation date changed from 1 Jun 2017 to 1 Nov 2017.